Applications Heavily Reliant On Foreign Data Get Positive Signals In US FDA Reviews

Agency has notably rejected some NDAs that relied solely on Chinese data, but a positive advisory committee for Geron’s proposed anemia treatment imetelstat and approval for BeiGene’s anti-PD-1 antibody Tevimbra suggest that using a lot of foreign data could be OK.

Asia strategy
BeiGene used a “more global approach to clinical trials” for the development of its PD-1 inhibitor. • Source: Shutterstock

More from China

More from Asia